P214 | PROGNOSTIC IMPACT OF EARLY SPLEEN RESPONSE IN POLYCYTHEMIA VERA PATIENTS TREATED WITH RUXOLITINIB: A REAL-WORLD COOPERATIVE STUDY

Ruxolitinib (RUX) is indicated for patients (pts) with Polycythemia Vera (PV) who are resistant/intolerant to hydroxyurea. To investigate early predictors of long-term outcome, we conducted a sub-analysis of the multicenter Italian “PV-ARC” study (NCT06134102), including 218 PV pts treated with 2<s...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	A. Dedola, C. Sartor, E.M. Elli, M. Breccia, R. Latagliata, A. Iurlo, E. Rossi, E. Morsia, N. Pugliese, F. Mendicino, A. Tieghi, G. Benevolo, G. Binotto, B. Martino, M. Farina, A. D’addio, M. Tiribelli, D. Cilloni, M. Crugnola, G. Caocci, D. Cattaneo, F. Cavalca, E. Scalzulli, F. Pane, G.A. Palumbo, F. Branzanti, V. De Stefano, F. Palandri
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Ferrata Storti Foundation 2025-09-01
Ráidu:	Haematologica
Liŋkkat:	https://haematologica.org/article/view/12309
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!